Evidence map›Paper›PMID 40594607›Full record

ArticleScientific reports2025

Simplified kinetic modeling for predicting the stability of complex biotherapeutics.

Mitja Zidar, Stefano Cucuzza, Matjaž Bončina, Drago Kuzman

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mitja ZidarNovartis Pharma AG, TRD Biologics & CGT, GDD, 4002, Basel, Switzerland.ORCID http://orcid.org/0000-0002-5655-6505
Stefano CucuzzaNovartis Pharma AG, TRD Biologics & CGT, GDD, 1234, Menges, Slovenia.ORCID http://orcid.org/0000-0001-6095-3194
Matjaž BončinaNovartis Pharma AG, TRD Biologics & CGT, GDD, 4002, Basel, Switzerland.
Drago KuzmanNovartis Pharma AG, TRD Biologics & CGT, GDD, 4002, Basel, Switzerland. drago.kuzman@novartis.com.ORCID http://orcid.org/0000-0003-4540-8619

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stability studies are vital in biologics development, guiding formulation, packaging, and shelf life determination. Traditionally, predicting long-term stability based on short-term data has been challenging due to the complex behavior of biologics. However, recently have been demonstrated that by using simple kinetics and the Arrhenius equation, it is possible to achieve accurate long-term stability predictions for various quality attributes, including protein aggregates. This study focuses on effective modeling of aggregate predictions for diverse protein modalities, such as IgG1, IgG2, Bispecific IgG, Fc fusion, scFv, bivalent nanobodies, and DARPins, using a first-order kinetic model. Notably, findings highlight the significance of temperature selection in stability studies, enabling the identification of dominant degradation processes. Additionally, simplicity of the first-order kinetic model enhances reliability by reducing the number of parameters and samples required. The model's effectiveness was further validated across various protein formats, beyond IgG, emphasizing its broad applicability and reliability. Compared to linear extrapolation, the kinetic model provided more precise and accurate stability estimates, even with limited data points. These findings highlight the benefits of using kinetic modeling with optimal temperature selection to predict protein aggregate stability and other quality attributes, aiding biologics development and shelf-life determination.

Indexed as

Biological ProductsDrug StabilityHumansImmunoglobulin GKineticsProtein StabilityTemperatureBiological ProductsImmunoglobulin GAggregationBiologicsKinetic modelingStability predictions

Identifiers

PMID40594607
PMCPMC12214494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.